New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
13:27 EDTSLXPFDA approves anti-diarrheal drug for HIV/AIDS patients distributed by Salix
The U.S. Food and Drug Administration approved Fulyzaq to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection. Before treating patients with Fulyzaq, health care professionals should conduct proper testing to confirm the diarrhea is not caused by an infection or a gastrointestinal disease. Common side effects reported in patients taking Fulyzaq in the clinical trial were upper respiratory tract infection, bronchitis, cough, flatulence, and increased levels of the liver enzyme bilirubin. Fulyzaq is distributed by Salix Pharmaceuticals under license from Napo Pharmaceuticals.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
18:18 EDTSLXPGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
October 21, 2014
07:07 EDTSLXPSalix to present results of TARGET 3 study with Rifaximin 550mg for IBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use